Targets › SNCA
6 programs from 6 companies in 11 trials: 6 Phase 2, 4 Phase 1, 1 Phase 3; Neurology, Other; next expected readout Jan 2027.
Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. (UniProt, P37840)
Open in Phaseline: the race on SNCA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Prasinezumab Alpha-synuclein binding agent | SNCA | Phase 3 | Parkinson's Disease; Parkinsons Disease | Jun 2029 |
| Teva Branded Pharmaceutical Products R&D | TEV-56286 alpha-synuclein aggregation inhibitor | SNCA | Phase 2 | Multiple System Atrophy; Healthy Volunteers | Jan 2027 |
| AC Immune | ACI-7104.056 Adjuvanted alpha-synuclein peptide conjugate vaccine | SNCA | Phase 2 | Parkinson Disease | Jun 2028 |
| XingImaging | [¹⁸F]MK-0947 alpha-synuclein (ASYN) PET imaging agent | SNCA | Phase 1 | Parkinsons Disease (PD) | Sep 2027 |
| University of Shizuoka | MF1 α-synuclein inhibitor | SNCA | Phase 1 | Healthy Adult Male | Sep 2028 |
| Regeneron Pharmaceuticals | ALN-SNCA SNCA mRNA inhibitor (siRNA) | SNCA | Phase 1 | Parkinsons Disease | Jun 2029 |
Parkinson's Disease (3) Multiple System Atrophy (2) Parkinsons Disease (2) Healthy Volunteers (1) Healthy Adult Male (1) Parkinson Disease (1) Parkinsons Disease (PD) (1)
small molecule (4), protein or peptide (1), antibody (1)
Teva Branded Pharmaceutical Products R&D (1) University of Shizuoka (1) AC Immune (1) Regeneron Pharmaceuticals (1) Roche (1) XingImaging (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.